Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

Oculis announced an R&D Day on December 8, 2026, to showcase its late-stage pipeline including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. Licaminlimab's PREDICT-1 registrational trial has completed patient randomization with topline results expected around year-end, while Privosegtor is advancing through the PIONEER program with anticipated IND clearance this quarter for acute MS relapse indication.